Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Clene Inc CLNN

Metals & Mining Silver
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic... see more

Current News (NDAQ:CLNN)

Clene Announces $7 Million Underwritten Offering of Common Stock

GlobeNewswire 3 days ago

Clene to Present at Upcoming May Conferences

GlobeNewswire 3 days ago

After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS

GlobeNewswire 4 days ago

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

GlobeNewswire March 12, 2026

Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts

GlobeNewswire February 24, 2026

Clene to Present at the Emerging Growth Conference

GlobeNewswire February 19, 2026

Clene to Present at the Emerging Growth Conference

GlobeNewswire January 16, 2026

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

GlobeNewswire January 12, 2026

Clene Announces Registered Direct Offering of Over $28 Million

GlobeNewswire January 9, 2026
View More News ››

Opinion & Analysis (NDAQ:CLNN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CLNN)

Clene Inc. (NASDAQ: CLNN): Revolutionizing Neurodegenerative

https://beyondspx.com/article/clene-inc-nasdaq-clnn-revolutionizing-neurodegenerative-disease-treatments-with-innovative-nanotech
MikeTester - January 22, 2025

BUY BUY BUY BUY BUY

Day after r.s. promissing conjoncture
Nibinator - July 11, 2024
View more Bullboard ››

Nurcapital Common Stock

Nurcapital Common Stock

Nurcapital Corporation Ltd. is a Canada-based capital pool company. The Company is engaged in identifying and evaluating ...
View More »

Podcasts